Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/04/2026 | Q4 | $11.3B | -- | -- | $0.61 | -- |
| 10/29/2025 | Q3 | $11B | $11.5B | $1.32 | $1.26 | $0.06 |
| 07/30/2025 | Q2 | $10.5B | $10.7B | $0.94 | $1.11 | -$0.17 |
| 04/30/2025 | Q1 | $10B | $9.5B | $0.99 | $1.04 | -$0.05 |
| 02/05/2025 | Q4 | $9.6B | $10.4B | $0.26 | $0.49 | -$0.23 |
| 10/30/2024 | Q3 | $10.4B | $10.4B | -$0.04 | $1.16 | -$1.20 |
| 07/31/2024 | Q2 | $9.6B | $9.9B | $0.72 | $0.98 | -$0.27 |
| 05/01/2024 | Q1 | $8.8B | $9.3B | $0.64 | $0.94 | -$0.29 |
| 01/31/2024 | Q4 | $9.7B | $10B | $0.21 | $0.77 | -$0.56 |
| 11/01/2023 | Q3 | $9.4B | $10.3B | $0.90 | $1.14 | -$0.24 |
| 07/26/2023 | Q2 | -- | $9B | $0.99 | -- | -- |
| 04/26/2023 | Q1 | -- | $8.4B | $0.89 | -- | -- |
| 02/01/2023 | Q4 | -- | $8.7B | $0.86 | -- | -- |
| 11/02/2022 | Q3 | -- | $9.2B | $6.22 | -- | -- |
| 07/27/2022 | Q2 | -- | $8.7B | $0.52 | -- | -- |
| 04/27/2022 | Q1 | -- | $9.6B | $1.19 | -- | -- |
| 02/09/2022 | Q4 | -- | $9.5B | $0.62 | -- | -- |
| 10/27/2021 | Q3 | -- | $9.1B | $0.79 | -- | -- |
| 07/28/2021 | Q2 | -- | $8.2B | $0.97 | -- | -- |
| 04/28/2021 | Q1 | -- | $10.2B | $0.73 | -- | -- |
| 02/03/2021 | Q4 | -- | $11.5B | $0.44 | -- | -- |
| 10/28/2020 | Q3 | -- | $11.2B | $0.80 | -- | -- |
| 07/29/2020 | Q2 | -- | $9.5B | $1.40 | -- | -- |
| 04/29/2020 | Q1 | -- | $11.6B | $1.00 | -- | -- |
| 02/05/2020 | Q4 | -- | $11.4B | $0.83 | -- | -- |
| 10/30/2019 | Q3 | -- | $11.6B | $0.96 | -- | -- |
| 07/24/2019 | Q2 | -- | $10B | $0.62 | -- | -- |
| 05/01/2019 | Q1 | -- | $10B | $0.54 | -- | -- |
| 02/06/2019 | Q4 | -- | $10.5B | $0.79 | -- | -- |
| 10/31/2018 | Q3 | -- | $10.5B | $0.93 | -- | -- |
| 07/25/2018 | Q2 | -- | $9.9B | $0.30 | -- | -- |
| 04/25/2018 | Q1 | -- | $10.1B | $0.39 | -- | -- |
| 02/07/2018 | Q4 | -- | $10.1B | -$0.37 | -- | -- |
| 10/25/2017 | Q3 | -- | $10.3B | $0.80 | -- | -- |
| 07/26/2017 | Q2 | -- | $9.4B | -$0.12 | -- | -- |
| 04/26/2017 | Q1 | -- | $9.1B | $0.66 | -- | -- |
| 02/08/2017 | Q4 | -- | $9.4B | $0.16 | -- | -- |
| 10/26/2016 | Q3 | -- | $9.9B | $0.54 | -- | -- |
| 07/27/2016 | Q2 | -- | $9.3B | -$0.32 | -- | -- |
| 04/27/2016 | Q1 | -- | $8.8B | $0.21 | -- | -- |
| 02/03/2016 | Q4 | -- | $9.5B | -$0.28 | -- | -- |
GSK Plc reported $11.5B worth of top line sales in its most recent quarter.
GSK Plc announced earnings per share of $1.32 which represents a beat of analyst forecast a $1.26 per share.
GSK Plc reported $8.5B that represents $4.15 per share over the last quarter.
GSK Plc's earnings are forecast to grow from $1.59 per share to $3.92 per share next year representing an increase of 169.11%.
GSK Plc's next earnings date is February 4, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.